INVA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

91.30M

+2.01%

101.53M

+10.59%

Estimates Revision

The market is revising Upward the revenue expectations for Innoviva, Inc. (INVA) for FY2025, with the revenue forecasts being adjusted by 4.87% over the past three months. During the same period, the stock price has changed by 4.81%.

Revenue Estimates for FY2025

Revise Upward

+4.87%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+31.46%

In Past 3 Month

Stock Price

Go Up

+4.81%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 32.00 USD with a low forecast of 17.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

1 Sell

Moderate Buy

Current: 20.270

Low

17.00

Averages

32.00

High

45.00

Current: 20.270

Low

17.00

Averages

32.00

High

45.00

H.C. Wainwright

Buy

maintain

$45 -> $46

2025-12-16

New

Reason

H.C. Wainwright

Price Target

$45 -> $46

2025-12-16

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Innoviva to $46 from $45 and keeps a Buy rating on the shares. The firm says zoliflodacin was approved on schedule.

Goldman Sachs

Sell

initiated

$17

2025-09-30

Reason

Goldman Sachs

Price Target

$17

2025-09-30

initiated

Sell

Reason

Goldman Sachs initiated coverage of Innoviva with a Sell rating and $17 price target. The stock's recent rally has raised the bar for the company's infectious disease platform platform going forward, the analyst tells investors in a research note. The firm believes Innoviva's 2031 royalty-related patent cliff will start to weigh on the stock's performance in 2026.

H.C. Wainwright

Raghuram Selvaraju

Buy

upgrade

$40 -> $45

2025-08-11

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$40 -> $45

2025-08-11

upgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Innoviva to $45 from $40 and keeps a Buy rating on the shares. The company's Q2 revenue and earnings outperformed expectations, the analyst tells investors in a research note.

Oppenheimer

Outperform

initiated

$35

2025-08-11

Reason

Oppenheimer

Price Target

$35

2025-08-11

initiated

Outperform

Reason

Oppenheimer initiated coverage of Innoviva with an Outperform rating and $35 price target. Innoviva is a holding company comprised of royalty distributions from Breo and Anoro, a specialty therapeutics unit with assets for treating acute critical care, and a strategic finance equity investments arm, the analyst tells investors in a research note. The firm believes the company's specialty therapeutics and royalty commercial results will drive share outperformance.

H.C. Wainwright

initiated

$40

2025-07-14

Reason

H.C. Wainwright

Price Target

$40

2025-07-14

initiated

Reason

H.C. Wainwright initiated coverage of Innoviva with a Buy rating and $40 price target. The firm says Innoviva is a diversified company marketing multiple commercial products that is benefiting from "durable" royalty streams on mass market respiratory disease franchises.

Cantor Fitzgerald

NULL -> Overweight

initiated

$26

2025-07-11

Reason

Cantor Fitzgerald

Price Target

$26

2025-07-11

initiated

NULL -> Overweight

Reason

Cantor Fitzgerald initiated coverage of Innoviva with an Overweight rating and $26 price target.

Valuation Metrics

The current forward P/E ratio for Innoviva Inc (INVA.O) is 9.75, compared to its 5-year average forward P/E of 11.78. For a more detailed relative valuation and DCF analysis to assess Innoviva Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

11.78

Current PE

9.75

Overvalued PE

17.88

Undervalued PE

5.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

7.20

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

9.79

Undervalued EV/EBITDA

4.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.44

Current PS

0.00

Overvalued PS

4.19

Undervalued PS

2.69

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

INVA News & Events

Events Timeline

No data

News

9.0

12-13NASDAQ.COM

FDA Greenlights Innoviva's NUZOLVENCE, the First Oral Treatment for Gonorrhea

9.0

12-12Newsfilter

Innoviva Receives FDA Approval for NUZOLVENCE to Treat Gonorrhea

9.0

12-12Businesswire

Innoviva Reports Positive Phase 3 Results for Zoliflodacin in Treating Gonorrhea

People Also Watch

Frequently Asked Questions

What is Innoviva Inc (INVA) stock price today?

The current price of INVA is 20.27 USD — it has increased 0.65 % in the last trading day.

What is Innoviva Inc (INVA)'s business?

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

What is the price predicton of INVA Stock?

What is Innoviva Inc (INVA)'s revenue for the last quarter?

Innoviva Inc revenue for the last quarter amounts to 107.80M USD, increased 20.44 % YoY.

What is Innoviva Inc (INVA)'s earnings per share (EPS) for the last quarter?

Innoviva Inc. EPS for the last quarter amounts to 1.06 USD, increased 5200.00 % YoY.

What changes have occurred in the market's expectations for Innoviva Inc (INVA)'s fundamentals?

How many employees does Innoviva Inc (INVA). have?

Innoviva Inc (INVA) has 127 emplpoyees as of December 16 2025.

What is Innoviva Inc (INVA) market cap?

Today INVA has the market capitalization of 1.51B USD.